Trade Summary

4 days ago, Crystal Adam, serving as President, R&D at Tango Therapeutics, Inc. (TNGX), sold 27,000 shares at $22.87 per share, for a total transaction value of $617,571.27. Following this transaction, Crystal Adam now holds 115,743 shares of TNGX.

This sale represents a 18.92% decrease in Crystal Adam's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 1, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, June 3, 2026 at 6:37 PM ET, 2 days after the trade was made.

Tango Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.